Arthur Furlan, Head of Strategic Partnerships at ODC Life Sciences, shared a post on LinkedIn:
“Pharma Companies Running Trials in Brazil.
This week, the American Society of Clinical Oncology (ASCO) annual meeting starts in Chicago, where sponsors, investigators, and industry leaders will share the latest developments shaping the future of oncology drug development.
Given the increasing interest in expanding clinical research to new countries, I took a closer look at the oncology clinical trial landscape in Brazil to understand how the market has evolved in recent years. Here are a few highlights:
Oncology trials have increased by 60% since the pandemic compared with the previous five-year period
50+ new sponsors have initiated oncology studies in Brazil since 2020 – most are biotech companies following the path established by large pharma.
Brazil currently has 561 active or recruiting oncology studies – an all-time high, with significant room for further growth as more global sponsors expand their presence in the country.
The attached analysis for ODC Life Sciences explores sponsor activity, therapeutic area trends, the origin of new market entrants, and the key factors driving Brazil’s growing role in global oncology research.
If you’re attending ASCO and evaluating opportunities in Brazil/LATAM as part of your clinical development strategy, let’s connect!.”
Other articles about ASCO on OncoDaily.